On September 28, GENSCRIPT BIO fell 3.12% in regular trading, trading at 41.08 HKD/share, with turnover of approximately 104 million HKD. The decline marks a renewed wave of profit-taking after the stock surged from around 32 HKD to above 43 HKD over the preceding sessions, significantly overshooting JPMorgan's target price of 41 HKD.

The selling pressure echoes a similar pattern observed on September 24, when the stock also pulled back after a rapid climb fueled by multiple catalysts including the company's partnership with Eli Lilly's AI-driven drug discovery platform Lilly TuneLab and broader CXO sector momentum. Notably, JPMorgan had already conducted a phased reduction of its stake on September 15, offloading approximately 33.75 million shares at an average price of 32.74 HKD — totaling roughly 1.105 billion HKD — bringing its long position from 7.37% down to 5.64%. The institutional de-risking, combined with the stock trading above the broker's published target, has intensified near-term selling pressure despite the company's fundamentally constructive outlook driven by AI-powered protein order growth and favorable policy support.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)